Mobocertinib is a drug that is commonly used to treat lung cancer, but there are some important things that patients need to be aware of when using it. Patients must use Mobocertinib strictly according to their doctor's instructions, including proper dosage and dosage. Following your doctor's instructions and paying attention to proper use, regular follow-up visits, and proper storage of the medication are essential for the efficacy and safety of Mobocertinib.

QTc prolongation and torsades de pointes

Mobocertinib causes life-threatening prolongation of rate-corrected QT (QTc), including fatal torsade de pointes.

Assess QTc and baseline electrolytes before initiating Mobocertinib, correct abnormalities in sodium, potassium, calcium, and magnesium, and monitor QTc and electrolytes regularly during treatment; Increase the frequency of monitoring in patients with risk factors for QTc prolongation, such as congenital QT prolongation syndrome, heart disease, or electrolyte abnormalities; Avoid concomitant use of drugs known to prolong the QTc interval and avoid concomitant use with strong or moderate CYP3A inhibitors, which may further prolong QTc; Depending on the severity of QTc prolongation, Mobocertinib capsules are suspended, dose reduced, or permanently discontinued.

Interstitial lung disease (ILD)/pneumonia

Mobocertinib can cause fatal interstitial lung disease (ILD)/pneumonia, and patients are monitored for new or worsening pulmonary symptoms that may be indicative of interstitial lung disease (ILD)/pneumonia.

Mobocertinib is discontinued immediately in patients with suspected interstitial lung disease (ILD)/pneumonitis and permanently if interstitial lung disease (ILD)/pneumonia is confirmed.

Cardiotoxicity

Mobocertinib can cause cardiotoxicity (including decreased ejection fraction, cardiomyopathy, and congestive heart failure), which can lead to fatal heart failure; Mobocertinib may cause QTc prolongation, resulting in torsade de pointes.

Monitoring of cardiac function, including assessment of left ventricular ejection fraction at baseline and during treatment, and suspension, dose reduction, or permanent discontinuation of Mobocertinib depending on severity.

Diarrhea

Taking Mobocertinib may cause severe diarrhea. Patients are advised to start antidiarrheal drugs (e.g., loperamide) and increase fluid and electrolyte intake when they have diarrhea or increased frequency of bowel movements. Electrolytes are monitored, and the drug is suspended, reduced, or permanently discontinued depending on severity.

Embryo-fetal toxicity

Inform pregnant women of potential risks to the fetus. Women of reproductive potential are advised to use effective non-hormonal contraceptives during treatment with Mobocertinib and for 1 month after the last dose. Men with female partners of reproductive potential are advised to use effective contraception during treatment with Mobocertinib and for 1 week after the last dose.